SPRY1 and neoplasm: SPRY1 and 2 were also identified as possible MT1-MMP targets, however, neither SPRY1 nor 2 showed any significant correlation with melanoma progression and importantly, did not correlate with MT1-MMP expression in either melanoma cell lines or tumor samples.